STUGERON Tablet

Active ingredients: Cinnarizine

Product name and form

Stugeron 15 mg tablets.

Pharmaceutical Form

White circular tablet with S/15 on one side and JANSSEN on the other side.

Qualitative and quantitative composition

Each tablet contains 15 mg cinnarizine.

Excipients with known effect: Each tablet contains 160 mg lactose monohydrate and 15 mg sucrose.

For the full list of excipients, see section 6.1.

Active Ingredient
Description

Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular smooth muscle by selectively inhibiting the calcium influx into depolarised cells, thereby reducing the availability of free Ca2+ ions for the induction and maintenance of contraction.

List of Excipients

Lactose monohydrate
Maize starch
Sucrose
Talc
Magnesium stearate
Polyvidone K90

Pack sizes and marketing

PVC/Aluminium foil blisters

or

Polystyrene tubs with polyethylene caps

Each pack containing 15, 25, 100, 250 or 1000 tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK

Marketing authorization dates and numbers

PL 00242/5009R

Date of first authorisation: 14 September 1989
Date of latest renewal: 21 August 2001

Drugs

Drug
Countries
Brazil, Cyprus, Spain, Ireland, Lithuania, Singapore, United Kingdom